94 results on '"DʼHaens G"'
Search Results
2. DOP083 The association of appendectomy and colorectal cancer in ulcerative colitis patients: a systematic review and meta-analysis
3. DOP063 Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis
4. DOP047 Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX
5. DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
6. OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM
7. Short‐ and medium‐term outcomes following primary ileocaecal resection for Crohnʼs disease in two specialist centres
8. Review article: dose optimisation of infliximab for acute severe ulcerative colitis
9. P665 Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohnʼs disease: a prospective study
10. P669 Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohnʼs disease: final data from PYRAMID registry
11. P640 Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective study
12. P611 Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy
13. P522 A multicenter study to validate Magnetic Resonance Enterography against histological assessments of stenotic disease in patients with Crohnʼs disease
14. P353 Long-term safety of adalimumab in patients with Crohnʼs disease: final data from PYRAMID registry
15. P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study
16. P066 Fibrostenotic phenotype of fibroblasts in Crohnʼs disease is dependent on tissue stiffness and reversed by LOX inhibition
17. P119 Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohnʼs disease: a SONIC post hoc analysis
18. P114 Fecal loss of infliximab is underestimated due to proteolysis
19. P050 Centrally-determined standardization of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter study
20. P007 Oral tyrosine kinase 2 inhibitor ameliorates T cell transfer colitis
21. DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohnʼs disease
22. DOP036 The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylation
23. DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohnʼs disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
24. DOP017 Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data
25. OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension
26. OP015 Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohnʼs disease: the LIR!C TRIAL
27. Clinical Decision Support Tools: The Evolution of a Revolution
28. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
29. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
30. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohnʼs disease
31. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
32. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
33. Remission status predicts work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term daily therapy with multimatrix mesalazine
34. Health-related quality of life varies as a function of remission status in patients with mild-to-moderate ulcerative colitis receiving short-term and long-term daily therapy with multimatrix mesalazine
35. Early reconstruction of the leaking ileal pouch-anal anastomosis: a novel solution to an old problem
36. Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
37. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohnʼs disease activity
38. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis
39. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis
40. Adalimumab maintains remission of Crohnʼs disease after up to 4 years of treatment: data from CHARM and ADHERE
41. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
42. The effect of appendectomy on the course of ulcerative colitis: a systematic review
43. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohnʼs disease
44. Significant Differences Between Crohnʼs Disease and Ulcerative Colitis Regarding the Impact of Body Mass Index and Initial Disease Activity on Responsiveness to Azathioprine: Results from a European Multicenter Study in 1,176 Patients
45. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
46. The risk of post-operative complications associated with infliximab therapy for Crohnʼs disease: a controlled cohort study
47. The impact of anti-TNF (Infliximab or Remicade®) on the surgical management of Crohnʼs disease
48. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease
49. Reliability of histologic assessment in patients with eosinophilic oesophagitis
50. Placebo response and remission rates in Ulcerative Colitis clinical trials: Systematic review and meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.